Filing Analysis
Kyntra Bio reported the results of its 2026 annual meeting of stockholders held on June 12, 2026. Stockholders elected a Class III director, approved executive compensation on an advisory basis, and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor.
📋 Key Facts
- Michael Kauffman, M.D., Ph.D. was elected as a Class III director with 96.04% of the voting shares (1,239,169 shares for).
- Executive compensation for named executive officers was approved on an advisory basis (1,242,005 shares for, 23,606 against).
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026 (2,712,825 shares for).
- The meeting took place on June 12, 2026.
Kyntra Bio received a final payment of $4.0 million from AstraZeneca, representing the final indemnity holdback from the sale of its China operations. This payment completes all financial obligations owed to the company under the Share Purchase Agreement dated February 20, 2025.
📋 Key Facts
- Received $4.0 million from AstraZeneca Treasury Limited on June 2, 2026.
- Payment represents the final holdback for indemnity claims from the sale of China operations.
- The original transaction closed on August 29, 2025, for total consideration of approximately $220 million ($85M enterprise value + $135M net cash).
- Previous payments included $210 million at closing and a $6.4 million adjustment payment in November 2025.
Kyntra Bio, Inc. announced its financial results for the first quarter ended March 31, 2026. The announcement was made via a press release furnished as an exhibit to the 8-K filing.
📋 Key Facts
- The filing reports financial results for the fiscal quarter ended March 31, 2026.
- The information was disclosed under Item 2.02 (Results of Operations and Financial Condition).
- A press release dated May 11, 2026, was included as Exhibit 99.1.
- The report was signed by David DeLucia, Senior Vice President and Chief Financial Officer.
Kyntra Bio, Inc. received a deficiency notice from Nasdaq on April 2, 2026, for failing to meet the $50 million total assets and revenue requirement for continued listing on the Nasdaq Global Select Market. The company also confirmed it does not meet alternative listing standards regarding shareholders' equity or market value of listed securities.
🚩 Red Flags
- Failure to meet multiple alternative listing standards (equity and market value) simultaneously.
- Significant revenue impact from assets held for sale/discontinued operations in consecutive years (2024-2025).
- Potential for delisting if a compliance plan is not accepted or executed.
📋 Key Facts
- Received Nasdaq notification on April 2, 2026, regarding non-compliance with Listing Rule 5450(b)(3)(A).
- Non-compliance resulted from FibroGen International revenue being classified as held for sale/discontinued operations in 2024 and 2025.
- The company currently fails alternative requirements for shareholders' equity and market value of listed securities.
- Kyntra Bio has 45 days (until May 18, 2026) to submit a compliance plan to Nasdaq.
- If the plan is accepted, an extension of up to 180 days (until September 29, 2026) may be granted.
- The company is considering a transfer to the Nasdaq Capital Market as a potential remedy.
Kyntra Bio, Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The results were disclosed via a press release furnished as Exhibit 99.1 to the filing.
📋 Key Facts
- Financial results reported for the quarter and year ended December 31, 2025
- Filing date and report date of March 16, 2026
- Information furnished under Item 2.02 (Results of Operations and Financial Condition)
- Signed by David DeLucia, Senior Vice President and Chief Financial Officer